Sumary of New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine:
- The team is already testing the vaccine as a single-dose regimen in a Phase 3 trial called ENSEMBLE, following its effectiveness at promoting immune responses among adult and elderly individuals in a Phase 1/2a study..
- However, a further dose could potentially improve the magnitude and durability of these immune responses, says the team from Janssen Vaccines and Prevention B.V..
- The study also showed that the one-dose regimen generated neutralizing antibody responses that lasted at least 14 weeks, thereby supporting the team decision to evaluate the single-dose regimen in the current Phase 3 ENSEMBLE trial..
- Challenges in the race to develop a safe and effective vaccine Since the COVID-19 pandemic began in Wuhan, China, late last year (2019), researchers have been racing to develop a safe and effective vaccine against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)..
- Although people of all ages are at risk of contracting SARS-CoV-2, the risk of developing severe COVID-19 increases with age, highlighting the importance of ensuring vaccines provide durable immunity among older individuals..
- About the Ad26.COV2.S vaccine candidate The Ad26.COV2.S vaccine candidate encodes a viral surface structure called the SARS-CoV-2 spike protein, which SARS-CoV-2 uses to bind to and infect host cells..
- However, “while the advantages of single-dose vaccines, especially for use during a pandemic, are obvious, multiple doses may potentially improve the magnitude and durability of immune responses,”.
- SARS-CoV-2 spike-specific antibody responses were tested every two weeks over a period of 14 weeks following the first vaccination using enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assay (psVNA)…